Gyre Therapeutics (GYRE) reported second-quarter 2026 revenue of $29.1 million, down from $29.7 million a year earlier. GAAP net loss was $14.3 million, compared with a net loss of $2.2 million in the same period of 2025, and GAAP basic EPS was $(0.12).
The company affirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million. Gyre also said China’s CDE accepted the NDA for F351 for CHB-induced liver fibrosis in May 2026 and highlighted the May closing of its approximately $300 million all-stock acquisition of Cullgen.
- Q2 2026 ETUARY sales were $28.0 million, compared with $23.5 million a year earlier.
- Cash, cash equivalents, bank deposits, short-term investment and long-term certificates of deposit totaled $103.2 million as of June 30, 2026.
- Six-month 2026 revenue was $53.5 million, compared with $60.3 million in the prior-year period.
- Six-month 2026 net loss was $32.8 million, compared with net income of $2.7 million a year earlier.
- Gyre expects the final patient in its Phase 3 pirfenidone pneumoconiosis trial to complete the study by the fourth quarter of 2026.
$GYRE Insider Trading Activity
$GYRE insiders have traded $GYRE stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $GYRE stock by insiders over the last 6 months:
- WEIGUO YE (Chief Operating Officer) has made 0 purchases and 14 sales selling 108,734 shares for an estimated $675,174.
- YING LUO (Chief Executive Officer) has made 0 purchases and 2 sales selling 10,315 shares for an estimated $82,927.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$GYRE Hedge Fund Activity
We have seen 32 institutional investors add shares of $GYRE stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 45,857 shares (-84.1%) from their portfolio in Q1 2026, for an estimated $319,623
- GOLDMAN SACHS GROUP INC added 42,014 shares (+135.1%) to their portfolio in Q1 2026, for an estimated $292,837
- BLACKROCK, INC. added 38,339 shares (+5.3%) to their portfolio in Q1 2026, for an estimated $267,222
- BANK OF NEW YORK MELLON CORP added 19,606 shares (+45.4%) to their portfolio in Q2 2026, for an estimated $129,203
- BARCLAYS PLC removed 16,231 shares (-87.6%) from their portfolio in Q1 2026, for an estimated $113,130
- DIMENSIONAL FUND ADVISORS LP added 14,365 shares (+131.8%) to their portfolio in Q1 2026, for an estimated $100,124
- STATE STREET CORP added 14,101 shares (+7.0%) to their portfolio in Q1 2026, for an estimated $98,283
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
